menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    RenovoRx Highlights Pharmacokinetic Data Presented at ASCO GI

    BUSINESSWIRE

    Kelun-Biotech`s Tagitanlimab Approved For Recurrent NPC Treatment

    PR NEWSWIRE

    Theriva Reaches VIRAGE Trial Enrollment For Pancreatic Cancer

    GLOBENEWSWIRE

    Immuneering Reports Positive Phase 2a Data For IMM-1-104

    GLOBENEWSWIRE

    RenovoRx Enrolls First Patient In Phase III TIGeR-PaC Trial At Nebraska Medical

    GLOBENEWSWIRE

    FibroGen Reports Pamrevlumab Pancreatic Cancer Study Results

    GLOBENEWSWIRE

    RenovoRx Announces Publication Acceptance In The Oncologist

    GLOBENEWSWIRE

    Precision-Panc Team Opens PRIMUS-006 Study For Gemcitabine, Pembrolizumab

    GLOBENEWSWIRE

    BMS`s Opdivo Combo Approved In EU For 1L Urothelial Carcinoma

    BUSINESSWIRE

    US FDA grants fast track designation to Theriva Biologics’ VCN-01

    PHARMABIZ

    Verastem Pancreatic Interim Positive: Avutometinib Defactinib Chemo Combo

    BUSINESSWIRE

    Zentalis Azenosertib Gemcitabine: Osteosarcoma Phase 1 At Asco 2024

    GLOBENEWSWIRE

    Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib

    PHARMABIZ

    CHMP Adopts Positive Opinion for Opdivo® in 1L Urothelial Cancer

    BUSINESSWIRE

    FDA Approves Opdivo for First-Line Treatment of Urothelial Carcinoma

    BUSINESSWIRE

    Polaris Initiates Ph 3 Trial: First Patient Dosed with ADI-PEG 20/Placebo

    GLOBENEWSWIRE

    Merck Receives Positive EU CHMP Opinion for KEYTRUDA for Biliary Tract Cancer

    BUSINESSWIRE

    FDA Approves Merck’s KEYTRUDA & Cisplatin as Treatment for Biliary Tract Cancer

    BUSINESSWIRE

    Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer

    ONCLIVE

    Preliminary Result with CYT-0851 in Advanced Solid Tumors Show Clinical Activity

    BUSINESSWIRE

    Panbela Announces First Patient Enrolled in ASPIRE Trial Studying Ivospemin

    GLOBENEWSWIRE

    Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin with Gemcitabine and Nab-Paclitaxel

    GLOBENEWSWIRE

    RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy

    BUSINESSWIRE

    Theriva Announces First Patient Dosed in Phase 2b VIRAGE Trial of VCN-01

    GLOBENEWSWIRE

    Tiziana Life Announces IND filed for Phase 2 of Milciclib with Gemcitabine

    GLOBENEWSWIRE

    Panbela Receives EMA Opinion on Orphan Designation for Ivospemin

    GLOBENEWSWIRE

    Panbela Receives Approvals to Open Sites in Spain, France & Italy for SBP-101

    GLOBENEWSWIRE

    Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101

    GLOBENEWSWIRE

    NuCana`s twist on chemo drug Gemzar fails in phase 3 again

    FIERCEPHARMA

    Enforcement Report - Week of February 2, 2022

    FDA

    Microcap cancer player goes belly up after pancreatic tumor drug flops key study

    ENDPTS

    Panbela Initiates ASPIRE Study of SBP-101 with Nab-Paclitaxel & Gemcitabine

    GLOBENEWSWIRE

    Panbela Presents Clinical Data on Phase 1b Trial of SBP-101 in Metastatic PDA

    GLOBENEWSWIRE

    Panavance Provides Update on Status of GP-2250 Trial in Pancreatic Cancer

    BUSINESSWIRE

    Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer

    GLOBENEWSWIRE

    Repare Doses First Patient in Phase 1 Clinical Trial of RP-6306 + Gemcitabine

    BUSINESSWIRE

    Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing

    GLOBENEWSWIRE

    Erytech`s eryaspase flunks late-stage pancreatic cancer trial; shares drop

    MARKETWATCH

    Bristol Myers` Abraxane falls into shortage from manufacturing woes

    ENDPTS

    Rafael Pharmaceuticals Initiates PII for CPI-613+Gemcitabine+Cisplatin in BTC

    GLOBENEWSWIRE

    Merck to discontinue PII study of bintrafusp alfa+gemcitabine+cisplatin for BTC

    PHARMABIZ

    Hikma Intl Pharms`s Generic Gemcitabine Hydrochloride Receives FDA Approval

    FDA

    Patent Expiry of Branded Oncology Products in Gemcitabine HCL Market

    PRNEWSWIRE

    Pamrevlumab Included in PCAN’s Adaptive Clinical Trial Platform

    GLOBENEWSWIRE

    AB Science announces results from masitinib study AB12005 presented at 2021 ASCO

    PRESS RELEASE

    NKMax, Merck expand clinical collaboration to include phase I/IIa trial of SNK01

    PHARMABIZ

    Nanjing King`s Generic Gemcitabine Hydrochloride Receives Approval in US

    FDA

    Innovent & Lilly At ESMO Presents Ph Iii Results Of Tyvyt® + Alimta®

    PRNEWSWIRE

    RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer

    PRNEWSWIRE

    Tyvyt® Combined with Gemzar® and Platinum Chemotherapy Met Predefined Endpoint

    PRNEWSWIRE

    Ascentage Pharma Announces Approval for the Ph Ib/II Clinical Trial of APG-1387

    PR NEWSWIRE

    AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab

    BUSINESSWIRE

    Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020

    PR NEWS WIRE

    BridgeBio Pharma`s QED Therapeutics Receives Fast Track Designation

    GLOBE NEWSWIRE

    After Cancer Drug Fails Pancreatic Cancer Trial, Lilly Plans to Continue Studies

    BIOSPACE

    Lilly`s Armo buyout drug a bust in pancreatic cancer

    FIERCE BIOTECH

    Shilpa Medicare`s Generic Gemcitabine Hydrochloride Receives Approval in US

    FDA

    Roche`s Tecentriq excels in another lung cancer study

    ENDPOINTSNEWS

    NuCana`s retooled chemo drug comes up short in pancreatic cancer

    FIERCE BIOTECH

    Another effort on pancreatic cancer flops, as Boston Biomedical cans Ph 3 test

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.